Who
Daniel Faga
President, CEO
Company insider
Files Form 4 as: President, CEO, First Tracks Biotherapeutics; President, CEO, AnaptysBio; EVP, Chief Operating Officer, Mirati Therapeutics; Chief Business Officer, Spark Therapeutics.
In numbers
- Trades disclosed
- 195
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $12.2M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 2 May 2016
- Last trade
- 15 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Aug 2026filed 18 Aug 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —193,575 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —193,575 at $0.00 | filing |
| 2 Aug 2026filed 5 Aug 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —193,576 at $0.00 | filing |
| 2 Aug 2026filed 5 Aug 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —193,576 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,200 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —271,100 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,200 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —271,100 at $0.00 | filing |
| 20 Apr 2026filed 23 Apr 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code D | —11,000 at $0.00 | filing |
| 20 Apr 2026filed 23 Apr 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code D | —11,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,512 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —98,600 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,321 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,321 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —194,900 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —379,620 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.